Development of oral HSV-1 infection model in mice. Evaluation of efficacy of 5′-amino-5-iodo-2′,5′-dideoxyuridine.

Daniel Albert // Publications // Mar 01 1982

PubMed ID: 6278378

Author(s): Park NH, Pavan-Langston D, Hettinger ME, Geary PA, August ML, Albert DM, Lin TS, Prusoff WH. Development of oral HSV-1 infection model in mice. Evaluation of efficacy of 5′-amino-5-iodo-2′,5′-dideoxyuridine. Oral Surg Oral Med Oral Pathol. 1982 Mar;53(3):256-62. PMID 6278378

Journal: Oral Surgery, Oral Medicine, And Oral Pathology, Volume 53, Issue 3, Mar 1982

We developed a new model of oral HSV-1 infection in mice. After oral inoculation, 100 percent of mice developed the clinical lesions at the inoculated area and latent HVS infection in their trigeminal ganglia without mortality. The antiherpetic efficacy of AIdUrd, an agent specifically activated by herpesvirus-encoded enzyme, has been evaluated in this animal model. Early topical or systemic treatment of AIdUrd notably reduced the development of clinical lesions and the virus content in the inoculated lips. However, the establishment of latent HSV infection in the sensory ganglia was not influenced by AIdUrd treatment.